Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Management reiterated its full-year revenue target of JPY460 billion and emphasized achieving JPY550 billion in FY2025. Growth is expected from the HIV franchise, global expansion of Xocova, and ...

S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received ...

Ironwood cuts 120 jobs (50% of workforce) amid apraglutide submission, Shionogi's RSV drug succeeds in Phase 2, and multiple companies announce deals and layoffs.

“Faisal has a proven track record in integrating cutting-edge science with practical, evidence-base PHILADELPHIA, October 24, 2024--New data for AREXVY, GSK’s RSV vaccine, show potential to ...

Dan Atkins, vice president of digital innovation and insight at Shionogi Europe ... for COVID-19 and respiratory syncytial virus (RSV). Join the conversation, on Tuesday 28th January @ 10 am ...

COVID-19 and flu activity is increasing in most parts of the country and RSV activity remains very high, especially in young children. Respiratory illness activity in Florida is very high ...

The report also showed emergency department visits for RSV — a common virus that typically causes mild, cold-like symptoms — are at "very high" levels in the state. ER visits for COVID-19 are ...

But there's a fourth "bug" the public should be aware of: respiratory syncytial virus. RSV causes cold-like symptoms and affects the breathing passages and lungs. Wastewater levels of RSV are ...

According to the CDC, cases of the cold, flu, COVID and RSV are rising and experts predict these numbers will continue to grow in the coming weeks. Some hospitals in the U.S. are seeing an ...

Pfizer and GSK vaccines will now be required to carry warnings that they may be tied to an increased risk of a rare neurological side effect. © 2024 Fortune Media IP ...